Peanut Allergy Treatment Results Will Debut in November
Aravax will present findings on its new immunotherapy, which aims to retrain the immune system in children with peanut allergies.
Updated on Oct. 6, 2026 in Allergies
Live Poll
Would you trust a new immunotherapy treatment to manage a severe food allergy for your family?
Aravax is set to release Phase 2 clinical trial results for its peanut allergy immunotherapy, PVX108, in November 2026. The study evaluated the treatment's safety and efficacy in adolescents and children aged four to eleven.
Why it matters
This research explores a potential new way to help children develop tolerance to peanuts while reducing the risk of treatment-induced allergic reactions. The FDA has granted Fast Track designation to PVX108, underscoring the clinical interest in this approach.
The Phase 2 study, which enrolled children aged four to eleven in the US and Australia, assessed PVX108 over a 12-month period. These trial results are preliminary until presented at upcoming scientific meetings.
The players
Aravax
An immunology company focused on developing peptide-based therapies to treat food allergies.
The details
PVX108 is an immunotherapy that uses proprietary peptides to retrain the immune system to tolerate peanut proteins. Unlike other forms of treatment, it is administered via intradermal injections. The therapy is designed to minimize the risk of acute allergic reactions that can sometimes occur during the desensitization process.
Timeline
November 12-16, 2026: ACAAI scientific meeting in Phoenix.
November 19-21, 2026: EAACI-FAAM-EUROBAT-ISMA congress in Utrecht.
Health Landscape
This development follows the path of the FDA Fast Track designation process, which prioritizes the review of therapies addressing serious unmet medical needs. It sits within a broader landscape of immunotherapy research aimed at shifting the standard of care for pediatric peanut allergies.
While these trial results may offer hope for future treatment options, they are not yet available for clinical use. Parents of children with peanut allergies should discuss their current management plans and any upcoming treatment options with their allergist.
The takeaway
Immunotherapy aims to help children tolerate food allergens, but these treatments must be carefully monitored for potential side effects. Always work with your physician to stay informed about new research and how it may fit into your child's long-term allergy management plan.
What happens next
Aravax will present trial data at the ACAAI meeting in Phoenix from November 12 to 16, 2026, and at the EAACI-FAAM-EUROBAT-ISMA congress in Utrecht from November 19 to 21, 2026.
Further reading
Learn more about the latest developments in pediatric care within our Allergies section.
More information
Find further details on the development of this immunotherapy on the Aravax company website.
Live Poll
Would you trust a new immunotherapy treatment to manage a severe food allergy for your family?
